Lobectomy: 173 Real Stories

173 stories match lobectomy. 84 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage I Lung Adenocarcinoma With Later Kidney Metastases Responding to Osimertinib

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; RB1 mutation; MAP3K1 mutation; PD-L1 negative

Metastatic Site: kidneys, peritoneal lymph nodes

Osimertinib produced a partial response within 6 weeks after metastatic recurrence in the kidneys. She remained alive and continued targeted treatment.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage I Lung AdenocarcinomaLung Cancer

Stage 1 lung adenocarcinoma: no recurrence after 2 years

Patient Info: Anonymized, Female, 50s | Stage I

No recurrence or surgical complications 2 years after uniportal video-assisted thoracoscopic left middle lobectomy and left upper-lobe wedge resection for Stage IB lung adenocarcinoma in situs inversus totalis.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage 4 lung LCNEC: major response to chemotherapy plus immunotherapy

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: Large-cell neuroendocrine lung cancer markers were positive. PD-L1 was negative

Metastatic Site: left adrenal gland

By July 2024, PET-CT showed complete metabolic response of the adrenal metastasis, no visible adrenal disease, no pulmonary recurrence, and no distant metastasis after immunochemotherapy, lobectomy, adjuvant therapy, and serplulimab maintenance.

PubMed Central
OutcomeCancer-Free / NED
Payton, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage III Lung Adenocarcinoma: Payton's Survivor Story

Patient Info: Payton Gibbs, Female, Under 40 | Stage III

As of August 2024, Payton described herself as cancer-free after lobectomy and 4 rounds of adjuvant chemotherapy.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage I Lung CancerLung Cancer

Stage 1 lung adenocarcinoma: NED after surgery alone

Patient Info: Anonymized, Male, 70+ | Stage I

Biomarkers: MET exon 14 skipping; PIK3CA p.; KRAS exon 2 p./D

Both independent early-stage lung adenocarcinomas were resected without lymph-node metastasis; follow-up showed normalized oncologic markers, negative lung-cancer autoantibodies, improved HRCT findings, and no recurrence for 1 year.

PubMed Central
OutcomeCancer-Free / NED
Att, who was diagnosed with Stage II Lung CancerLung Cancer

Stage II Lung Cancer: Att's Patient Story

Patient Info: Att Callahan, Female, 70+ | Stage II

As of July 2024, Att was receiving monthly post-surgery immunotherapy and scans every other month after clinical-trial chemoimmunotherapy and lobectomy, with doctors believing they had removed all visible cancer.

MD Anderson
OutcomeCare Ongoing
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Stage IIIA EGFR-mutated lung adenocarcinoma: surgery after osimertinib

Patient Info: Anonymized, Male, 60s

Biomarkers: EGFR E746_A750 deletion; PD-L1 TPS 15%; TMB 5.01 Muts/Mb; TTF-1 3+; CK7 3+; Ki67 60%

As of July 2024, surveillance CT scans at 2, 6, and 12 months after surgery showed no recurrent malignancy while he continued adjuvant osimertinib.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage II Lung AdenocarcinomaLung Cancer

Guillain-Barré syndrome after surgery for Stage II lung adenocarcinoma

Patient Info: Anonymized, Male, 70+ | Stage II

No lung-cancer recurrence was seen at follow-up after complete resection. His postoperative Guillain-Barré syndrome resolved within 3 months after immunoglobulin treatment and rehabilitation.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

RET-fusion lung adenocarcinoma responding to pralsetinib and bevacizumab

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: KIF13A-RET fusion

Metastatic Site: pleura

He had 27 months of disease-free survival on pralsetinib before pleural and nodal recurrence. After bevacizumab was added, imaging showed reduction of the pleural lesion and mediastinal nodes and circulating tumor DNA became undetectable in December 2023.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage 3 EGFR-mutant lung cancer: osimertinib response to surgery

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: EGFR exon 19 deletion; PD-L1 tumor proportion score <=1%

No recurrence or metastasis was reported after neoadjuvant osimertinib, R0 left upper lobectomy with mediastinal lymphadenectomy, and ongoing adjuvant osimertinib for Stage IIIA EGFR exon 19 deletion lung adenocarcinoma.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage IIIA NSCLC: recurrence-free after surgery, adjuvant chemotherapy, and one atezolizumab dose

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: PD-L1 expression 20% by 22C3 assay

She remained free of lung-cancer recurrence for more than 1 year after surgery and adjuvant cisplatin/vinorelbine; atezolizumab was stopped after 1 dose because of severe immune-related toxicities that improved with steroid and immunoglobulin treatment.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

EGFR-mutant lung adenocarcinoma in Li-Fraumeni syndrome: relapse-free after lobectomy and chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Lung tumor had EGFR exon 19 deletion. Germline TP53 variant was consistent with Li-Fraumeni syndrome; prior breast cancers were HER2 positive.

As of July 2024, she was free of relapse 2 years after left inferior lobectomy and pemetrexed/cisplatin for EGFR exon 19 deletion lung adenocarcinoma.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR-mutated lung cancer treated with osimertinib during tuberculosis therapy

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: pleura, left axillary lymph node

Osimertinib maintained a partial response throughout 9 months of tuberculosis treatment, with no new abdominal or brain lesions. By the end of tuberculosis treatment, she was more than 7 years from her original lung-cancer diagnosis.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IVA lung adenocarcinoma with solitary brain metastasis: pCR after brain surgery, chemoradiation, immunotherapy, and lobectomy

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 75%; negative for driver gene mutations and translocations

Metastatic Site: brain

As of May 2024, he had no recurrence after brain metastasis resection and radiation, carboplatin/pemetrexed/atezolizumab, robot-assisted right upper lobectomy with pathologic complete response, and 13 cycles of maintenance atezolizumab.

PubMed Central
OutcomeCancer-Free / NED